Gerd Zettlmeissl
Chairman en MEDIGENE AG .
Perfil
Gerd Zettlmeissl is currently the Chairman-Supervisory Board at MediGene AG since 2019, Chairman-Supervisory Board at MSD Wellcome Trust Hilleman Laboratories Pvt Ltd.
since 2013, and Director at Aeras Global TB Vaccine Foundation since 2011.
Previously, he served as Chairman-Management Board at Intercell AG from 2010 to 2011, Chairman at GlycoVaxyn AG from 2013 to 2015, Chairman at DMS Imaging SA from 2017 to 2018, and Chairman-Supervisory Board at Themis Bioscience GmbH from 2015 to 2020.
He also held positions at Chiron Behring & Co., Helmholtz-Zentrum für Infektionsforschung GmbH, and Chiron Corp.
Dr. Zettlmeissl holds a doctorate degree from the University of Regensburg.
Cargos activos de Gerd Zettlmeissl
Empresas | Cargo | Inicio |
---|---|---|
MEDIGENE AG | Chairman | 22/05/2019 |
Aeras Global TB Vaccine Foundation
Aeras Global TB Vaccine Foundation Miscellaneous Commercial ServicesCommercial Services Aeras Global TB Vaccine Foundation is a non-profit organization, which engages in the development of tuberculosis vaccines in partnership with other biotech, pharmaceutical, and academic organizations. Its product pipeline includes AdS Ag85A, MTBCAV, VPM 1002, and RUTI. The company is headquartered in Rockville, MD. | Director/Board Member | 14/11/2011 |
MSD Wellcome Trust Hilleman Laboratories Pvt Ltd.
MSD Wellcome Trust Hilleman Laboratories Pvt Ltd. BiotechnologyHealth Technology MSD Wellcome Trust Hilleman Laboratories Pvt Ltd. develops and researches vaccines. The joint venture company is based in Gurgaon, India. The company was founded in 2009. Raman Rao has been the CEO of the Indian company since 2020. | Chairman | 01/01/2013 |
Antiguos cargos conocidos de Gerd Zettlmeissl.
Empresas | Cargo | Fin |
---|---|---|
Themis Bioscience GmbH
Themis Bioscience GmbH Pharmaceuticals: MajorHealth Technology Themis Bioscience GmbH operates as a biotechnology company, which engages in the development of prophylactic vaccinations from preclinical to early clinical phase. The firm focuses on the prevention of tropical infectious diseases. Its proprietary Themaxyn technology platform, in-licensed from Paris-based Institute Pasteur, forms the basis of all of the company's vaccine candidates. The company was founded by Erich Tauber in 2009 and is headquartered in Vienna, Austria. | Chairman | 01/01/2020 |
DMS IMAGING | Chairman | 18/12/2018 |
GlycoVaxyn AG
GlycoVaxyn AG BiotechnologyHealth Technology GlycoVaxyn AG developed and produced bioconjugate vaccines. The company was founded in 2004 and was headquartered in Schlieren, Switzerland. | Chairman | 01/01/2015 |
Intercell AG
Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | Chief Executive Officer | 10/05/2011 |
Chiron Corp.
Chiron Corp. Medical SpecialtiesHealth Technology Chiron Corp. provides nucleic acid test for blood screening. Its products include tigris system, target capture system, reagent preparation incubator, and many more. The company was founded in 1981 by William J. Rutter, Edward E. Penhoet & Pablo Valenzuela and is headquartered in Emeryville, CA. | Chief Tech/Sci/R&D Officer | - |
Formación de Gerd Zettlmeissl.
University of Regensburg | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 2 |
---|---|
MEDIGENE AG | Health Technology |
DMS IMAGING | Health Technology |
Empresas privadas | 8 |
---|---|
Chiron Corp.
Chiron Corp. Medical SpecialtiesHealth Technology Chiron Corp. provides nucleic acid test for blood screening. Its products include tigris system, target capture system, reagent preparation incubator, and many more. The company was founded in 1981 by William J. Rutter, Edward E. Penhoet & Pablo Valenzuela and is headquartered in Emeryville, CA. | Health Technology |
Intercell AG
Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | Health Technology |
Aeras Global TB Vaccine Foundation
Aeras Global TB Vaccine Foundation Miscellaneous Commercial ServicesCommercial Services Aeras Global TB Vaccine Foundation is a non-profit organization, which engages in the development of tuberculosis vaccines in partnership with other biotech, pharmaceutical, and academic organizations. Its product pipeline includes AdS Ag85A, MTBCAV, VPM 1002, and RUTI. The company is headquartered in Rockville, MD. | Commercial Services |
Chiron Behring & Co.
Chiron Behring & Co. Medical DistributorsDistribution Services Part of Novartis AG, Chiron Behring & Co. is a German company that supplies and develops new vaccine products for adults and children. The company is based in Marburg, Germany. Chiron Behring was acquired by Chiron Corp. from Hoechst AG on April 01, 1998 for $111.90 million. | Distribution Services |
GlycoVaxyn AG
GlycoVaxyn AG BiotechnologyHealth Technology GlycoVaxyn AG developed and produced bioconjugate vaccines. The company was founded in 2004 and was headquartered in Schlieren, Switzerland. | Health Technology |
Helmholtz-Zentrum für Infektionsforschung GmbH
Helmholtz-Zentrum für Infektionsforschung GmbH BiotechnologyHealth Technology Helmholtz-Zentrum für Infektionsforschung GmbH provides bio-medical research and development services. The firm engages in research projects focused on infection biology and its clinical application and practical implementation. It also specializes in the examination of pathogens that are either medically relevant or that can be used as models for the research of infections. Its research topics encompass bacterial and viral pathogens, immune response, and anti-infectives. The company was founded in 1965 and is headquartered in Braunschweig, Germany. | Health Technology |
Themis Bioscience GmbH
Themis Bioscience GmbH Pharmaceuticals: MajorHealth Technology Themis Bioscience GmbH operates as a biotechnology company, which engages in the development of prophylactic vaccinations from preclinical to early clinical phase. The firm focuses on the prevention of tropical infectious diseases. Its proprietary Themaxyn technology platform, in-licensed from Paris-based Institute Pasteur, forms the basis of all of the company's vaccine candidates. The company was founded by Erich Tauber in 2009 and is headquartered in Vienna, Austria. | Health Technology |
MSD Wellcome Trust Hilleman Laboratories Pvt Ltd.
MSD Wellcome Trust Hilleman Laboratories Pvt Ltd. BiotechnologyHealth Technology MSD Wellcome Trust Hilleman Laboratories Pvt Ltd. develops and researches vaccines. The joint venture company is based in Gurgaon, India. The company was founded in 2009. Raman Rao has been the CEO of the Indian company since 2020. | Health Technology |
- Bolsa de valores
- Insiders
- Gerd Zettlmeissl